PT1135168E - Vectores peptidicos de substancias atraves da barreira hemato-encefalica - Google Patents

Vectores peptidicos de substancias atraves da barreira hemato-encefalica

Info

Publication number
PT1135168E
PT1135168E PT99972931T PT99972931T PT1135168E PT 1135168 E PT1135168 E PT 1135168E PT 99972931 T PT99972931 T PT 99972931T PT 99972931 T PT99972931 T PT 99972931T PT 1135168 E PT1135168 E PT 1135168E
Authority
PT
Portugal
Prior art keywords
hemato
substances
encephalic barrier
peptidic vectors
peptidic
Prior art date
Application number
PT99972931T
Other languages
English (en)
Inventor
Jamal Temsamani
Michel Kaczorek
Clair Philippe
Original Assignee
Synt Em Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synt Em Sa filed Critical Synt Em Sa
Publication of PT1135168E publication Critical patent/PT1135168E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Image Analysis (AREA)
PT99972931T 1998-11-30 1999-11-26 Vectores peptidicos de substancias atraves da barreira hemato-encefalica PT1135168E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9815074A FR2786397B1 (fr) 1998-11-30 1998-11-30 Vecteurs peptidiques de substances a travers la barriere hematoencephalique pour etre utilises dans le diagnostic ou la therapie d'une affection du snc

Publications (1)

Publication Number Publication Date
PT1135168E true PT1135168E (pt) 2005-09-30

Family

ID=9533370

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99972931T PT1135168E (pt) 1998-11-30 1999-11-26 Vectores peptidicos de substancias atraves da barreira hemato-encefalica

Country Status (12)

Country Link
US (1) US7399747B1 (pt)
EP (1) EP1135168B1 (pt)
JP (1) JP2002531420A (pt)
AT (1) ATE293460T1 (pt)
AU (1) AU777811B2 (pt)
CA (1) CA2352491A1 (pt)
DE (1) DE69924870T2 (pt)
ES (1) ES2242453T3 (pt)
FR (1) FR2786397B1 (pt)
IL (2) IL143010A0 (pt)
PT (1) PT1135168E (pt)
WO (1) WO2000032236A1 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19933492B4 (de) * 1999-07-16 2008-01-10 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Konjugat zur Vermittlung eines zell-, kompartiment- oder membranspezifischen Transports von Wirksubstanzen, Verfahren zu dessen Herstellung und dessen Verwendung
GB0103110D0 (en) 2000-08-25 2001-03-28 Aventis Pharma Inc A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1
FR2821272B1 (fr) * 2001-02-23 2004-12-17 Synt Em Composes constitues d'une molecule analgesique liee a un vecteur capable de vectoriser ladite molecule a travers la barriere hematoencephalique et compositions pharmaceutiques les contenant
FR2829940A1 (fr) * 2001-09-27 2003-03-28 Synt Em Compositions pour la vectorisation d'anticorps a travers la barriere hematoencephalique et leur utilisation pour le diagnostic ou le traitement des maladies du systeme nerveux central
FR2830016B1 (fr) * 2001-09-27 2004-06-25 Synt Em Compositions pour la vectorisation de derives taxoides a travers la barriere hematoencephalique et leur utilisation pour le traitement des cancers, plus particulierement des cancers du cerveau
FR2840810B1 (fr) * 2002-06-18 2005-02-11 Synt Em Composition pour le transfert de molecules therapeutiques dans les poumons et leur utilisation pour le traitement des cancers du poumon et des maladies pulmonaires
FR2849603B1 (fr) * 2003-01-07 2006-09-08 Centre Nat Rech Scient Composition pour le transport intracellulaire de macromolecules ou particules biologiques
CN101084002B (zh) * 2004-09-02 2015-01-21 克格诺西有限公司 改进的apo e类似物及其使用方法
US8034762B2 (en) * 2004-09-02 2011-10-11 Cognosci, Inc. Treatment of subarachnoid hemorrhage with Apo E analogs
CA2692847A1 (en) * 2007-07-31 2009-02-05 Cognosci, Inc. Methods of inhibiting calcineurin with apoe analogs
US10245098B2 (en) 2008-04-29 2019-04-02 Virginia Tech Intellectual Properties, Inc. Acute blood-brain barrier disruption using electrical energy based therapy
US10117707B2 (en) 2008-04-29 2018-11-06 Virginia Tech Intellectual Properties, Inc. System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies
US11272979B2 (en) 2008-04-29 2022-03-15 Virginia Tech Intellectual Properties, Inc. System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies
US11254926B2 (en) 2008-04-29 2022-02-22 Virginia Tech Intellectual Properties, Inc. Devices and methods for high frequency electroporation
US9198733B2 (en) 2008-04-29 2015-12-01 Virginia Tech Intellectual Properties, Inc. Treatment planning for electroporation-based therapies
WO2009134876A1 (en) 2008-04-29 2009-11-05 Virginia Tech Intellectual Properties, Inc. Irreversible electroporation to create tissue scaffolds
US9867652B2 (en) 2008-04-29 2018-01-16 Virginia Tech Intellectual Properties, Inc. Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds
US9283051B2 (en) 2008-04-29 2016-03-15 Virginia Tech Intellectual Properties, Inc. System and method for estimating a treatment volume for administering electrical-energy based therapies
US10702326B2 (en) 2011-07-15 2020-07-07 Virginia Tech Intellectual Properties, Inc. Device and method for electroporation based treatment of stenosis of a tubular body part
US8992517B2 (en) 2008-04-29 2015-03-31 Virginia Tech Intellectual Properties Inc. Irreversible electroporation to treat aberrant cell masses
US10272178B2 (en) 2008-04-29 2019-04-30 Virginia Tech Intellectual Properties Inc. Methods for blood-brain barrier disruption using electrical energy
US10238447B2 (en) 2008-04-29 2019-03-26 Virginia Tech Intellectual Properties, Inc. System and method for ablating a tissue site by electroporation with real-time monitoring of treatment progress
US11638603B2 (en) 2009-04-09 2023-05-02 Virginia Tech Intellectual Properties, Inc. Selective modulation of intracellular effects of cells using pulsed electric fields
US11382681B2 (en) 2009-04-09 2022-07-12 Virginia Tech Intellectual Properties, Inc. Device and methods for delivery of high frequency electrical pulses for non-thermal ablation
WO2010138919A2 (en) 2009-05-28 2010-12-02 Angiodynamics, Inc. System and method for synchronizing energy delivery to the cardiac rhythm
US9895189B2 (en) 2009-06-19 2018-02-20 Angiodynamics, Inc. Methods of sterilization and treating infection using irreversible electroporation
EP2627274B1 (en) 2010-10-13 2022-12-14 AngioDynamics, Inc. System for electrically ablating tissue of a patient
FR2968662B1 (fr) 2010-12-10 2013-11-22 Roussy Inst Gustave Nouveaux derives d'oxazaphosphorines pre-activees, utilisation et methode de preparation
WO2012088149A2 (en) 2010-12-20 2012-06-28 Virginia Tech Intellectual Properties, Inc. High-frequency electroporation for cancer therapy
US9078665B2 (en) 2011-09-28 2015-07-14 Angiodynamics, Inc. Multiple treatment zone ablation probe
CN106715682A (zh) 2014-05-12 2017-05-24 弗吉尼亚暨州立大学知识产权公司 使用脉冲电场选择性调节细胞的胞内影响
US10694972B2 (en) 2014-12-15 2020-06-30 Virginia Tech Intellectual Properties, Inc. Devices, systems, and methods for real-time monitoring of electrophysical effects during tissue treatment
US10905492B2 (en) 2016-11-17 2021-02-02 Angiodynamics, Inc. Techniques for irreversible electroporation using a single-pole tine-style internal device communicating with an external surface electrode
US11607537B2 (en) 2017-12-05 2023-03-21 Virginia Tech Intellectual Properties, Inc. Method for treating neurological disorders, including tumors, with electroporation
US11925405B2 (en) 2018-03-13 2024-03-12 Virginia Tech Intellectual Properties, Inc. Treatment planning system for immunotherapy enhancement via non-thermal ablation
US11311329B2 (en) 2018-03-13 2022-04-26 Virginia Tech Intellectual Properties, Inc. Treatment planning for immunotherapy based treatments using non-thermal ablation techniques
US11950835B2 (en) 2019-06-28 2024-04-09 Virginia Tech Intellectual Properties, Inc. Cycled pulsing to mitigate thermal damage for multi-electrode irreversible electroporation therapy
WO2021028614A1 (en) * 2019-08-14 2021-02-18 Nokia Technologies Oy Method and apparatus for handling non-integrity protected reject messages in non-public networks

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2739621B1 (fr) * 1995-10-05 1997-12-05 Centre Nat Rech Scient Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives
US5843903A (en) * 1995-11-27 1998-12-01 The Administrators Of The Tulane Educational Fund Targeted cytotoxic anthracycline analogs
WO1998046250A1 (en) * 1997-04-14 1998-10-22 The Regents Of The University Of California Peptide antiestrogen compositions and methods for treating breast cancer
FR2767323B1 (fr) * 1997-08-12 2001-01-05 Synt Em Peptides lineaires derives de peptides antibiotiques, leur preparation et leur utilisation pour vectoriser des substances actives
CZ20011671A3 (cs) * 1998-11-13 2001-10-17 Cyclacel Limited Peptidová nosná skupina pro transport

Also Published As

Publication number Publication date
ATE293460T1 (de) 2005-05-15
EP1135168B1 (fr) 2005-04-20
DE69924870D1 (de) 2005-05-25
US7399747B1 (en) 2008-07-15
WO2000032236A1 (fr) 2000-06-08
IL143010A0 (en) 2002-04-21
AU1391000A (en) 2000-06-19
CA2352491A1 (fr) 2000-06-08
FR2786397B1 (fr) 2003-01-10
IL143010A (en) 2006-04-10
FR2786397A1 (fr) 2000-06-02
EP1135168A1 (fr) 2001-09-26
JP2002531420A (ja) 2002-09-24
DE69924870T2 (de) 2006-02-23
ES2242453T3 (es) 2005-11-01
AU777811B2 (en) 2004-11-04

Similar Documents

Publication Publication Date Title
PT1135168E (pt) Vectores peptidicos de substancias atraves da barreira hemato-encefalica
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
GR3031488T3 (en) Laminin chains: diagnostic and therapeutic use
ATE280783T1 (de) Monoklonale anti-cd6 antikörper zur behandlung und diagnose von psoriasis
ATE519776T1 (de) Peptidische verbindungen
DE820303T1 (de) p277 PEPTIDANALOGE, PHARMAZEUTISCHE ZUSAMMENSTELLUNG DAVON ZUR BEHANDLUNG UND DIAGNOSE VON DIABETES
PT750672E (pt) Sequencias de adn para metaloproteases matriciais, sua preparacao e utilizacao.
HUP0102479A2 (hu) Neisseria meningitidis-ből származó BASBO29-polinukleotid(ok) és polipeptidek
DE69329656D1 (de) Methoden zur detektion und behandlung von individuen mit abnormalen hla-a2/tyrosinase-peptidantigenen exprimierenden zellen
ATE258057T1 (de) Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen
NO913129L (no) Nytt trombolytisk middel.
IL159479A (en) Glycopeptides, their preparation and use in the diagnosis or therapeutic treatment of multiple sclerosis
HUP9903688A2 (hu) Olanzapin alkalmazása az autizmus kezelésére szolgáló gyógyszerkészítmény előállítására
ATE411390T1 (de) Synthetische säugetier alpha-n- acetylglukosaminidase und dafür kodierende genetische sequenzen
ATA77095A (de) Stabiles präparat zur behandlung von blutgerinnungsstörungen, enthaltend eine aktive gerinnungsfördernde stubstanz
DE59510686D1 (de) Komplexverbindungen zur diagnose von gefässerkrankungen
IT1270614B (it) Proteine ad attivita' antitumorale da organi di mammiferi
DE3779283D1 (de) Zwei-phasen-shampoo zur reinigung, pflege und medizinischen behandlung.
ATE76282T1 (de) Zwei-phasen-shampoo zur reinigung, pflege und medizinischen behandlung.
ATE209941T1 (de) Arzneigeräte für die behandlung von blutgefässen mittels ionisierungsbestrahlung
KR19980085707A (ko) 기를 이용한 질병 치료 기구
UA39811A (uk) Спосіб діагностики нефроптозу та больового поперекового синдрому, пов'язаного з патологічно рухливою ниркою
DE69016135T2 (de) Diagnostikgerät zur funktionellen Untersuchung des Kreislaufsystems.